CoChat
Sign Up
Cited by 810Extracellular vesicles in diseaseMicroRNA in disease regulationCancer-related molecular mechanisms research

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Circulating Exosomal microRNAs as Biomarkers of Colon Cancer

Open access
Ogata-Kawata, Hiroko, Izumiya, Masashi, Kurioka, Daisuke, Honma, Yoshitaka, Yamada, Yasuhide, Furuta, Koh, Gunji, Toshiaki, Ohta, Hideki, Okamoto, Hiroyuki, Sonoda, Hikaru, Watanabe, Masatoshi, Nakagama, Hitoshi, Yokota, Jun, Kohno, Takashi, Tsuchiya, Naoto·2014·PLoS ONE
DOI 10.1371/journal.pone.0092921PMC PMC3976275
Open this paper in CoChat — free accountOpen PDF

Abstract

PURPOSE: Exosomal microRNAs (miRNAs) have been attracting major interest as potential diagnostic biomarkers of cancer. The aim of this study was to characterize the miRNA profiles of serum exosomes and to identify those that are altered in colorectal cancer (CRC). To evaluate their use as diagnostic biomarkers, the relationship between specific exosomal miRNA levels and pathological changes of patients, including disease stage and tumor resection, was examined. EXPERIMENTAL DESIGN: Microarray analyses of miRNAs in exosome-enriched fractions of serum samples from 88 primary CRC patients and 11 healthy controls were performed. The expression levels of miRNAs in the culture medium of five colon cancer cell lines were also compared with those in the culture medium of a normal colon-derived cell line. The expression profiles of miRNAs that were differentially expressed between CRC and control sample sets were verified using 29 paired samples from post-tumor resection patients. The sensitivities of selected miRNAs as biomarkers of CRC were evaluated and compared with those of known tumor markers (CA19-9 and CEA) using a receiver operating characteristic analysis. The expression levels of selected miRNAs were also validated by quantitative real-time RT-PCR analyses of an independent set of 13 CRC patients. RESULTS: The serum exosomal levels of seven miRNAs (let-7a, miR-1229, miR-1246, miR-150, miR-21, miR-223, and miR-23a) were significantly higher in primary CRC patients, even those with early stage disease, than in healthy controls, and were significantly down-regulated after surgical resection of tumors. These miRNAs were also secreted at significantly higher levels by colon cancer cell lines than by a normal colon-derived cell line. The high sensitivities of the seven selected exosomal miRNAs were confirmed by a receiver operating characteristic analysis. CONCLUSION: Exosomal miRNA signatures appear to mirror pathological changes of CRC patients and several miRNAs are promising biomarkers for non-invasive diagnosis of the disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0092921

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Strategy for the identification of CRC-specific exosomal miRNAs.
Figure 1 Strategy for the identification of CRC-specific exosomal miRNAs.CC BY · PubMed Central
Figure 2 Serum exosomal expression levels of 16 miRNAs that were up-regulated in colon cancer. Serum exosomal miRNA levels in 11 HCs (blue) and 88 CRC patients (red) at different TNM stages (I to IV). The signal intensities were normalized to the total signal intensity of the microarray. The horizontal lines indicate the mean normalized signal intensity for each group. Statistically significant differences were determined by Welch's t-test.
Figure 2 Serum exosomal expression levels of 16 miRNAs that were up-regulated in colon cancer. Serum exosomal miRNA levels in 11 HCs (blue) and 88 CRC patients (red) at different TNM stages (I to IV). The signal intensities were normalized to the total signal intensity of the microarray. The horizontal lines indicate the mean normalized signal intensity for each group. Statistically significant differences were determined by Welch's t-test.CC BY · PubMed Central
Figure 3 Exosomal miRNA levels in matched serum samples from CRC patients before and after tumor resection. (A) Scatter plot of the 16 commonly up-regulated serum exosomal miRNAs in CRC patients (n = 29) before (Pre) and after (Post) surgical removal of tumors. The sample set included stage I (n = 6), stage II (n = 6), stage IIIa (n = 5), stage IIIb (n = 9), and stage IV (n = 4) patients. The data represent the mean normalized signal intensities (%). The red dots indicate the eight miRNAs that were significantly down-regulated after tumor resection: let-7a, miR-1224-5p, miR-1229, miR-1246, miR-150, miR-21, miR-223, and miR-23a. (B) Individual changes in the serum exosome levels of the eight down-regulated miRNAs in CRC patients (n = 29) before (Pre) and after (Post) surgical removal of tumors. Statistically significant differences between the mean Pre values and the mean Post values were determined by paired Student's t-tests.
Figure 3 Exosomal miRNA levels in matched serum samples from CRC patients before and after tumor resection. (A) Scatter plot of the 16 commonly up-regulated serum exosomal miRNAs in CRC patients (n = 29) before (Pre) and after (Post) surgical removal of tumors. The sample set included stage I (n = 6), stage II (n = 6), stage IIIa (n = 5), stage IIIb (n = 9), and stage IV (n = 4) patients. The data represent the mean normalized signal intensities (%). The red dots indicate the eight miRNAs that were significantly down-regulated after tumor resection: let-7a, miR-1224-5p, miR-1229, miR-1246, miR-150, miR-21, miR-223, and miR-23a. (B) Individual changes in the serum exosome levels of the eight down-regulated miRNAs in CRC patients (n = 29) before (Pre) and after (Post) surgical removal of tumors. Statistically significant differences between the mean Pre values and the mean Post values were determined by paired Student's t-tests.CC BY · PubMed Central
Figure 4 ROC curve analysis of eight miRNAs in serum exosomes of HCs and CRC patients. The signal intensities of the miRNAs are shown as percentages of the total signal intensity. The cut-off values of the eight miRNAs that were up-regulated in colon cancer and down-regulated after tumor resection were analyzed using a ROC curve. Black boxes indicate patients over the cut-off value of the biomarkers or miRNA levels. The normalized intensities of undetectable miRNAs in serum exosomes were calculated as 0.
Figure 4 ROC curve analysis of eight miRNAs in serum exosomes of HCs and CRC patients. The signal intensities of the miRNAs are shown as percentages of the total signal intensity. The cut-off values of the eight miRNAs that were up-regulated in colon cancer and down-regulated after tumor resection were analyzed using a ROC curve. Black boxes indicate patients over the cut-off value of the biomarkers or miRNA levels. The normalized intensities of undetectable miRNAs in serum exosomes were calculated as 0.CC BY · PubMed Central
Figure 5 Validation of CRC-associated increases in the expression of eight miRNA in serum exosomes by qRT-PCR. Box-and-whisker plots of the expression levels of the eight selected miRNAs in an independent set of HCs (n = 8) and CRC patients with primary tumor (n = 13). Statistically significant differences between the HC and CRC datasets were determined by Welch's t-tests. The comparative cycle threshold (Ct) method was used to quantify the levels of exosomal miRNAs in HC and CRC patients. The relative ratio was calculated using the 2-ΔΔCt method. The Ct value of miR-451 was used as an internal standard. Each data point was normalized to a representative HC sample.
Figure 5 Validation of CRC-associated increases in the expression of eight miRNA in serum exosomes by qRT-PCR. Box-and-whisker plots of the expression levels of the eight selected miRNAs in an independent set of HCs (n = 8) and CRC patients with primary tumor (n = 13). Statistically significant differences between the HC and CRC datasets were determined by Welch's t-tests. The comparative cycle threshold (Ct) method was used to quantify the levels of exosomal miRNAs in HC and CRC patients. The relative ratio was calculated using the 2-ΔΔCt method. The Ct value of miR-451 was used as an internal standard. Each data point was normalized to a representative HC sample.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 37 references

Cited by

Sorted by citations

Items 801–810 of 810

Related

See all

Metadata

Authors
Ogata-Kawata, H., Izumiya, M., Kurioka, D., Honma, Y., Yamada, Y., Furuta, K., Gunji, T., Ohta, H., Okamoto, H., Sonoda, H., Watanabe, M., Nakagama, H., Yokota, J., Kohno, T., & Tsuchiya, N.
Affiliations
  • University of Tokyo Hospital (JP)
  • Yokohama National University (JP)
  • National Cancer Center Hospital (JP)
  • NTT Medical Center (JP)
  • Shionogi (Japan) (JP)
  • National Cancer Center Research Institute (JP)
  • Institute of Predictive and Personalized Medicine of Cancer (ES)
Corresponding author
Tsuchiya, Naoto
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2014-04-04
Volume
9
Issue
4
Pages
e92921
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0092921
PMC
PMC3976275
OpenAlex
W1992970284
Cited by
809
References
37
Citations by year
2026: 28 · 2025: 37 · 2024: 51 · 2023: 45 · 2022: 76 · 2021: 96 · 2020: 89 · 2019: 81 · 2018: 76 · 2017: 76 · 2016: 78 · 2015: 60 · 2014: 15
FWCI
31.32
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Institute of Biomedical Innovation
  • Japan Society for the Promotion of Science (23300359, 24790683)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
Keywords
exosomal microRNAs, colorectal cancer, serum exosomes, diagnostic biomarkers, non-invasive diagnosis, miR-21, miR-223, miR-23a, miR-150, miR-1246, let-7a, tumor resection, CA19-9, carcinoembryonic antigen
MeSH terms
Adult, Aged, Colonic Neoplasms, Female, Humans, Male, Middle Aged, Tumor Cells, Cultured, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Case-Control Studies, HT29 Cells, Gene Expression Profiling, MicroRNAs, HCT116 Cells, Cell Line, Tumor, Microarray Analysis, Exosomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review